A Phase I dose-escalation study of the BRAF inhibitor vemurafenib in combination with the MTOR inhibitor everolimus in subjects with advanced cancer
Dissertations and Theses (Open Access)
Part of the Medicine and Health Sciences Commons
Part of the Medicine and Health Sciences Commons